Moderna submits amendment to the emergency use authorization for an additional booster dose of its covid-19 vaccine in the u.s.

Cambridge, ma / accesswire / march 17, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it has submitted a request to the u.s. food and drug administration (fda) for an amendment to the emergency use authorization (eua) to allow for a fourth dose of its covid-19 vaccine (mrna-1273) in adults 18 years of age and older who have received an initial booster of any of the authorized or approved covid-19 vaccines. the request to include adults over 18 years of age was made to provide flexibility for the u.s. centers for disease control and prevention (cdc) and healthcare providers to determine the appropriate use of an additional booster dose of mrna-1273, including for those at higher risk of covid-19 due to age or comorbidities.
MRNA Ratings Summary
MRNA Quant Ranking